| Name | Title | Contact Details |
|---|---|---|
Andre Garcia |
Chief Information and Technology Officer | Profile |
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
LaserSight Incorporated is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The employees of SynergEyes are committed to provide the highest quality, technologically advanced hybrid contact lenses that address a wide spectrum of vision conditions, while continuously meeting the needs of today's Practitioner and Patient.
SNBL USA is a part of the SNBL Group of companies and is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL). As part of the SNBL Group, SNBL USA shares the corporate mission statement: We are committed to freeing patients from suffering by
OrthoIndy is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.